Intangible assets

The carrying amount of intangible assets mainly comprises goodwill on the acquisition of NeoResins in 2005 (€358 million), Crina in 2006 (€9 million) and Pentapharm in 2007 (€36 million). For further information on these assets including the discussion of the related impairment tests, please refer to Note 8 'Intangible assets' in the 'Notes to the consolidated financial statements of Royal DSM'.